Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

Philippe Colombat 1, * Nicole Brousse 2 Gilles Salles 3 Franck Morschhauser 4 Pauline Brice 5 Pierre Soubeyran 6 Vincent Delwail 7 Eric Deconinck 8 Corinne Haioun 9 Charles Foussard 10 Catherine Sebban 11 Hervé Tilly 12 Catherine Thieblemont 5 L. Bergougnoux 13 F. Lazreg 13 Philippe Solal-Celigny 14
* Auteur correspondant
1 Service d'hématologie [Tours]
2 Service d'anatomie pathologique [CHU Necker]
3 Service d'Hematologie
4 Service d'hématologie
5 Service d'hématologie-oncologie adultes
6 Plateforme de génétique moléculaire des cancers d'Aquitaine
7 Service d'Anatomie et de Cytologie Pathologiques [Poitiers]
8 Service d'hématologie
9 Service d'hématologie clinique
10 Service d'hématologie
11 Service d'Oncologie Médicale
12 Service d'oncologie
13 Service d'Hématologie
14 Onco-radiothérapie, hématologie
Abstract : BACKGROUND: The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). PATIENTS AND METHODS: Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m(2)), 46 have been followed with a long-term analysis of clinical and molecular responses. RESULTS: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4-92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. CONCLUSION: A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
Type de document :
Article dans une revue
Annals of Oncology, Oxford University Press (OUP), 2012, 23 (9), pp.2380-5. 〈10.1093/annonc/mds177〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00821113
Contributeur : Philippe Saas <>
Soumis le : mardi 7 mai 2013 - 15:14:31
Dernière modification le : jeudi 6 septembre 2018 - 01:17:30

Lien texte intégral

openaccess

Identifiants

Collections

HCL | UNIV-POITIERS | UNIV-PARIS5 | UPEC-UPEM | USPC | BERGONIE | FNCLCC | BECQUEREL | CHLS

Citation

Philippe Colombat, Nicole Brousse, Gilles Salles, Franck Morschhauser, Pauline Brice, et al.. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.. Annals of Oncology, Oxford University Press (OUP), 2012, 23 (9), pp.2380-5. 〈10.1093/annonc/mds177〉. 〈inserm-00821113〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

207

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD